💰 SUN’s 1Q EPS remained flat at LKR 0.34 as PATMI stood at LKR 665mn (-1.4% YoY) amidst margin contractions stemming from Healthcare and Agribusiness. Group topline witnessed a 17% YoY growth to LKR 18.5bn led by Consumer. 📘 BRS Outlook: Full recovery in healthcare margins is expected only by 2H FY27E. Local pharma manufacturing through Zydus Sunshine Lifesciences JV to be operational from CY2028. branded tea export volumes should see a recovery in 2Q FY27E as deferred 1Q volumes roll over. The outlook for agribusiness remains positive.